302912-19-2

Basic information

• Product Name: 3-FLUORO-5-(TRIFLUOROMETHYL)PHENYL
• Synonyms: 3-FLUORO-5-(TRIFLUOROMETHYL)PHENYL;Benzene, 1-fluoro-3-isocyanato-5-(trifluoromethyl)- (9CI);3-Fluoro-5-(trifluoromethyl)phenyl isocyanate, 97+%;3-Fluoro-5-(trifluoromethyl)phenyl isocyanate 97%
• CAS NO: 302912-19-2
• Molecular Formula: C₈H₃F₄NO
• Molecular Weight: 205.11
• Product Categories: ISOCYANATE;Isocyanates;Nitrogen Compounds;Organic Building Blocks
• Mol File: 302912-19-2.mol

Chemical Properties

• Boiling Point: 164 °C(lit.)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.423 g/mL at 25 °C(lit.)
• Vapor Pressure: 1.33mmHg at 25°C
• Refractive Index: n20/D 1.446(lit.)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-FLUORO-5-(TRIFLUOROMETHYL)PHENYL(CAS DataBase Reference)
• NIST Chemistry Reference: 3-FLUORO-5-(TRIFLUOROMETHYL)PHENYL(302912-19-2)
• EPA Substance Registry System: 3-FLUORO-5-(TRIFLUOROMETHYL)PHENYL(302912-19-2)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38-42
• Safety Statements: 23-26-36
• WGK Germany: 3
• Hazardous Substances Data: 302912-19-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Fluoro-5-(trifluoromethyl)phenyl isocyanate is used as a reactant for the synthesis of RIP1 kinase inhibitors. These inhibitors are crucial in the treatment of pathologies associated with necroptosis, a form of programmed cell death that occurs in response to various cellular stressors and can contribute to the development of various diseases.
The application of this compound in the pharmaceutical industry is significant due to its role in the development of potential therapeutic agents that can target and modulate the activity of RIP1 kinase, thereby providing a novel approach to treating necroptosis-related conditions.

InChI:InChI=1/C8H3F4NO/c9-6-1-5(8(10,11)12)2-7(3-6)13-4-14/h1-3H

Upstream product

• 454-67-1 3-fluoro-5-trifluoromethylaniline 
• 503-38-8 trichloromethyl chloroformate 

Downstream Products

• 307985-13-3 4-[1-(4-cyclohexylphenyl)-3-(3-fluoro-5-trifluoromethylphenyl)ureidomethyl]-N-(2H-tetrazol-5-yl)benzamide 
• 960312-52-1 C₂₅H₂₉F₄N₃O₂ 
• 1006867-19-1 C₂₀H₂₅F₄N₃O₃ 
• 929195-17-5 C₂₃H₂₉F₄N₃O 
• 1374006-33-3 C₁₇H₁₅F₄N₃O₂ 
• 1374006-45-7 C₂₂H₁₇F₄N₃O₂ 
• 1421283-97-7 1-(3-fluoro-5-(trifluoromethyl)phenyl)-3-(5-nitroisoquinolin-1-yl)urea 
• 1467739-12-3 1-(3-(2-amino-6-oxo-1,6-dihydropyrimidin-4-ylamino)-4-methylphenyl)-3-(3-fluoro-5-(trifluoromethyl)phenyl)-urea 
• 1314678-97-1 1-(3-fluoro-5-trifluoromethylphenyl)-3-(4-nicotinoylpyrimidin-2-yl)urea 

Relevant articles and documents

GLUCAGON ANTAGONISTS/INVERSE AGONISTS

A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-

Glucagon antagonists/inverse agonists

Disclosed is a novel class of compounds of formula (I) wherein V, A, Y, Z, R1, E, X and D are as defined in the specification. These compounds act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor, the compounds are suitable for treating or preventing glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.